253 related articles for article (PubMed ID: 20160740)
1. The economics of drug development: a grim reality and a role for clinical pharmacology.
Honig P; Lalonde R
Clin Pharmacol Ther; 2010 Mar; 87(3):247-51. PubMed ID: 20160740
[No Abstract] [Full Text] [Related]
2. ASCPT Task Force for advancing pharmacometrics and integration into drug development.
Goldberger MJ; Singh N; Allerheiligen S; Gobburu JV; Lalonde R; Smith B; Ryder S; Yozviak A
Clin Pharmacol Ther; 2010 Aug; 88(2):158-61. PubMed ID: 20648032
[TBL] [Abstract][Full Text] [Related]
3. European lead factory opens for business.
Mullard A
Nat Rev Drug Discov; 2013 Mar; 12(3):173-5. PubMed ID: 23449292
[No Abstract] [Full Text] [Related]
4. Bringing DNA vaccines closer to commercial use.
Carvalho JA; Prazeres DM; Monteiro GA
IDrugs; 2009 Oct; 12(10):642-7. PubMed ID: 19790015
[TBL] [Abstract][Full Text] [Related]
5. The challenge of complexity.
Dollery CT
Clin Pharmacol Ther; 2010 Jul; 88(1):13-5. PubMed ID: 20562888
[No Abstract] [Full Text] [Related]
6. Precompetitive research: a new prescription for drug development?
Woodcock J
Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
[No Abstract] [Full Text] [Related]
7. Next-generation model-based drug discovery and development: quantitative and systems pharmacology.
Allerheiligen SR
Clin Pharmacol Ther; 2010 Jul; 88(1):135-7. PubMed ID: 20531467
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacy in the 1980s.
Smith WE
Am J Hosp Pharm; 1983 Feb; 40(2):223-9. PubMed ID: 6829578
[No Abstract] [Full Text] [Related]
9. Searching for scalable processes: addressing the challenges in times of increasing complexity.
Federsel HJ
Curr Opin Drug Discov Devel; 2003 Nov; 6(6):838-47. PubMed ID: 14758755
[TBL] [Abstract][Full Text] [Related]
10. Viewpoint: pharmaceutical innovation in Europe.
Baines E
Circulation; 2007 Jan; 115(2):f5-6. PubMed ID: 17228009
[No Abstract] [Full Text] [Related]
11. Improving productivity with model-based drug development: an enterprise perspective.
Grasela TH; Slusser R
Clin Pharmacol Ther; 2010 Aug; 88(2):263-8. PubMed ID: 20592720
[No Abstract] [Full Text] [Related]
12. [Crucial tasks of pharmacologists of the USSR in accelerating scientific and technological progress].
Val'dman AV
Farmakol Toksikol; 1986; 49(6):5-15. PubMed ID: 3817145
[No Abstract] [Full Text] [Related]
13. Drug discovery and natural products: end of an era or an endless frontier?
Li JW; Vederas JC
Science; 2009 Jul; 325(5937):161-5. PubMed ID: 19589993
[TBL] [Abstract][Full Text] [Related]
14. Benefit-risk assessment: to quantify or not to quantify, that is the question.
Yuan Z; Levitan B; Berlin JA
Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):653-6. PubMed ID: 21538675
[No Abstract] [Full Text] [Related]
15. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
Ichimaru K; Toyoshima S; Uyama Y
Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
[No Abstract] [Full Text] [Related]
16. NIPTE: a multi-university partnership supporting academic drug development.
Gurvich VJ; Byrn SR
Drug Discov Today; 2013 Oct; 18(19-20):916-21. PubMed ID: 23732177
[TBL] [Abstract][Full Text] [Related]
17. [History of clinical pharmacology in France: adaptation, evaluation, defense and illustration of drug in France 1978-1981].
Montastruc P
Therapie; 2014; 69(6):481-2. PubMed ID: 25320940
[TBL] [Abstract][Full Text] [Related]
18. Appropriate selection of biochemical targets is one of the most important driver of cost-effectiveness in the discovery of new medicines. Preface.
Lawton G; Witty DR
Prog Med Chem; 2008; 46():v-vi. PubMed ID: 18381122
[No Abstract] [Full Text] [Related]
19. Data warehousing.
Derendorf H
Int J Clin Pharmacol Ther; 2002 Mar; 40(3):S1-2. PubMed ID: 11911605
[No Abstract] [Full Text] [Related]
20. Control of high cost medicines.
Jones SW
N Z Med J; 1994 Mar; 107(974):113. PubMed ID: 8127514
[No Abstract] [Full Text] [Related]
[Next] [New Search]
